Top 20 biopharma companies see 7.9% increase in aggregate revenue in 2024: GlobalData
Seven out of the top 20 companies registered over 10 per cent YoY revenue growth from 2023 to 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Astellas Pharma
Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030
GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…
Lupin launches Mirabegron Extended-Release Tablets in the US
Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of $ 1,600 million in the US (IQVIA MAT July 2024)
Astellas’ fezolinetant fails to meet pre-defined endpoints for efficacy in Moonlight clinical…
Based on the 12-week data analysis in 302 participants, fezolinetant 30 mg once daily (QD) in women in China, Korea and Taiwan did…
Healthcare industry reports 58 deals worth $12.4 bn in Dec’19
According to GlobalData, three big ticket deals together contributed 63 per cent to the total deal value in the month
Strides Pharma Science arm gets US FDA nod for drug to treat overactive bladder
The approved product is a generic version of Vesicare tablets of Astellas Pharma US